Why It Matters

The House Energy and Commerce Subcommittee on Health convened on Wednesday to examine ten public health bills even as the Trump administration has proposed a 26 percent cut to the Department of Health and Human Services. The tension between what Congress is building legislatively and what the executive branch is cutting administratively defined the hearing's undercurrent.

The Big Picture

This congressional hearing roundup covers a subcommittee session driven primarily by urgency: at least five of the ten bills under review are reauthorizations of programs facing imminent expiration. The ACT for ALS Reauthorization Act, for instance, expires in September 2026. The School-Based Health Centers Reauthorization Act would extend $55 million annually beyond the current fiscal year authorization. The hearing also marked one of the first major sessions under the new Subcommittee Chair Rep. Morgan Griffith (R-VA), who assumed the gavel after Rep. Buddy Carter stepped down in July 2025 to pursue a Georgia Senate bid. Ranking Member Rep. Diana DeGette (D-CO) participated alongside Rep. Frank Pallone Jr. (D-NJ), who delivered Democratic opening remarks, sending a signal of minority engagement rather than obstruction.

What They're Saying

The hearing testimony summary drew from six witnesses spanning community health, oncology, microbiology, stem cell research, ALS patient advocacy, and digital health policy.

Jamie Ulmer, President and CEO, Healthcare Network (the primary voice for federally qualified health centers) testified that his organization served more than 56,000 patients in 2025 with over 220,000 visits, delivering $19 million in uncompensated care. He pressed for investment in school-based health, nutrition access, and behavioral health integration: "Community health centers are a proven, cost-effective solution. We can reach more patients earlier before conditions worsen and costs escalate."

Dr. Rachel F. Brem, Co-Founder and Chief Medical Officer, Brem Foundation to Defeat Breast Cancer, testified in support of the EARLY Act Reauthorization, drawing on both clinical data and personal experience. She told the subcommittee that breast cancer is now the most commonly diagnosed cancer in women aged 20 to 49, and that Black women under 50 are twice as likely to die from it as white counterparts: "Early detection is not just a recommendation. It's a right. And it's a right we must ensure for every woman."

The most emotionally charged witness testimony came from Brian Wallach and Sandra Abrevaya, Co-Founders, I AM ALS. Wallach, who has lived with ALS for eight years and can no longer speak or move, delivered his statement through eye-typing technology. He and Abrevaya co-authored the original 2021 Act for ALS. They appeared before the same subcommittee to advocate for its reauthorization: "Anyone who stands in the way of Act for ALS reauthorization is standing in the way of our best shot at survival."

Rep. John James (R-MI) responded directly to Wallach and Abrevaya: "I really want to commend and thank Mr. Wallach and Mrs. Abrevaya for your courage, for your resilience, and for your continued advocacy."

Holly Ahern, Associate Professor of Microbiology, SUNY Adirondack, testified in support of the Kay Hagan Tick Act Reauthorization, citing her daughter's experience going from a college athlete to "bedbound, paralyzed on one side" due to a missed Lyme disease diagnosis. She presented data showing tick infection rates in Ohio jumped from 2 percent in 2010 to nearly 50 percent by 2024 (a 2,300 percent increase) while the state reported only a fraction of the cases neighboring Pennsylvania documented: "Does it truly make sense that there are so few cases of Lyme disease in a state where half the ticks carry the bacteria?"

Amy L. Ronneberg, CEO, National Marrow Donor Program, testified that the program has facilitated nearly 150,000 transplants and improved donor match rates from 50 percent five years ago to 99 percent today for adult patients with common blood cancers. She noted the program has "never missed a cell delivery, even during challenging times like the pandemic."

René Quashie, Vice President of Digital Health, Consumer Technology Association, testified in support of the Digital Health Screeners Act of 2026, a pre-introduction bill the subcommittee is using this hearing to shape. He described the regulatory gap in consumer wearables and called for a federal privacy framework: "The United States does not have comprehensive federal privacy laws, and we need one."

Chair Griffith asked Quashie to follow up on wearable health technology, signaling that additional correspondence or a subsequent hearing on digital health tools may follow.

Political Stakes

The hearing's political stakes are layered. For Griffith, it is a credibility-building exercise in his first major session as subcommittee chair. Moving a bipartisan package of reauthorizations demonstrates legislative competence ahead of the 2026 midterms, particularly in a rural Virginia district where community health centers and tick-borne illness programs carry direct constituent relevance.

The White House has proposed a $93.8 billion HHS budget, a 26 percent reduction from the prior fiscal year. Several bills under review, including the community health center access bill and the nutrition education measure, direct funding through the very infrastructure the administration has been cutting.

Democrats on the subcommittee, including Rep. Robin Kelly (D-IL), used the hearing to draw that contrast directly, pressing Dr. Brem on how budget cuts and Medicaid reductions would worsen racial disparities in breast cancer outcomes for Black and Brown women.

The Act for ALS, which Wallach and Abrevaya helped write in 2021, represents the largest federal investment in ALS research in history. Reauthorization before its September 2026 expiration is the central ask. The ALS Association, the Muscular Dystrophy Association, and the ALS Network have all issued coordinated statements calling for swift passage.

Hearing Updates News

The bipartisan atmosphere of the hearing obscures a real tension in the legislative environment. Authorization and appropriation are separate tracks. Congress can reauthorize these programs, but the administration controls whether the money actually flows. Democrats have documented that some community health and Head Start programs were sporadically blocked from funding under the current administration, forcing some to shut down.

The Digital Health Screeners Act and the Nutrition Education and Chronic Disease Prevention in Community Health Centers Act remain pre-introduction bills, meaning this hearing is partly a scoping exercise. Their final text has not been set, and industry advocates (including the Consumer Technology Association) are actively shaping what those bills will say.

The Bottom Linbe

The bills examined on Wednesday were introduced in a coordinated batch in early April 2026, suggesting committee leadership is packaging them for a markup. The First Focus Campaign for Children has already submitted a letter of support for the school-based health centers bill. The Senate companion to the Kay Hagan Tick Act has already cleared committee with unanimous approval, led by Senators Susan Collins (R-ME) and Tina Smith (D-MN). A House floor vote on a combined health reauthorization package remains the most likely pathway.

House Republicans are building a bipartisan public health record, but whether the programs they reauthorize survive the administration's budget knife is an entirely separate fight.

Access the Legis1 platform for comprehensive political news, data, and insights.